li

From Control to Crisis: Changing Trends and Policies Reshaping U.S.-Mexico Border Enforcement

How did the U.S. border enforcement picture go in the span of two years from the lowest levels of illegal immigration since 1971 to a spiraling border security and humanitarian crisis? This report draws on enforcement and other data as well as analysis of changing migration trends and policies to tell this story. The authors outline key elements for a new strategy that can succeed over the long term.




li

Colts QB Philip Rivers to coach at Alabama high school once NFL career ends

Indianapolis Colts quarterback Philip Rivers will become the head football coach at St. Michael Catholic High School, the school announced Friday.




li

FDA approves first at-home saliva test for COVID-19

The first COVID-19 test using saliva samples that patients collect at home has been approved by the U.S. Food and Drug Administration.




li

Planet already seeing temps beyond human tolerability

Researchers have predicted that if climate change goes unabated, the planet will experience intolerable heat in several decades. But a new study has found that in certain global hot spots, it's already happening.




li

Metabolic Effects of Dietary Sucrose in Type II Diabetic Subjects

John P Bantle
Sep 1, 1993; 16:1301-1305
Short Report




li

Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia

Pratik Choudhary
Jun 1, 2015; 38:1016-1029
Type 1 Diabetes at a Crossroads




li

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms

Angelo Avogaro
May 1, 2011; 34:S285-S290
Hypertension




li

Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes: The TODAY clinical trial

TODAY Study Group
Jun 1, 2013; 36:1758-1764
TODAY Study




li

The Reality of Type 2 Diabetes Prevention

Richard Kahn
Apr 1, 2014; 37:943-949
Current Concepts of Type 2 Diabetes Prevention




li

Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Ian H. de Boer
Jan 1, 2014; 37:24-30
DCCT/EDIC 30th Anniversary Summary Findings




li

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013

Kasia J. Lipska
Apr 1, 2017; 40:468-475
Emerging Science and Concepts for Management of Diabetes and Aging




li

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Hannele Yki-Järvinen
Dec 1, 2014; 37:3235-3243
Emerging Technologies and Therapeutics




li

Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study

Lalantha Leelarathna
Jul 1, 2014; 37:1931-1937
Emerging Technologies and Therapeutics




li

Feasibility of Outpatient Fully Integrated Closed-Loop Control: First studies of wearable artificial pancreas

Boris P. Kovatchev
Jul 1, 2013; 36:1851-1858
Diabetes Care Symposium




li

Psychosocial Problems and Interventions in Diabetes: A review of the literature

Richard R Rubin
Nov 1, 1992; 15:1640-1657
Behavioral Diabetes Series




li

Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia

Bernhard J. Hering
Jul 1, 2016; 39:1230-1240
Emerging Technologies and Therapeutics




li

Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial

Roman Hovorka
May 1, 2014; 37:1204-1211
Advances in Artificial Pancreas Development




li

Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes

Ruth L. Coleman
May 1, 2007; 30:1292-1293
BR Cardiovascular and Metabolic Risk




li

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo
Oct 1, 2013; 36:3169-3176
Emerging Technologies and Therapeutics




li

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Robert R. Henry
Mar 1, 2015; 38:412-419
Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters




li

Vitamin E Reduction of Protein Glycosylation in Diabetes: New Prospect for Prevention of Diabetic Complications?

Antonio Ceriello
Jan 1, 1991; 14:68-72
Short Report




li

Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action

Boris Draznin
Jul 1, 2013; 36:1807-1814
Perspectives in Care




li

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans-Ulrich Häring
Jun 1, 2014; 37:1650-1659
Emerging Technologies and Therapeutics




li

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino
Aug 1, 2019; 42:1593-1603
International Consensus Report




li

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

Michaela Diamant
Oct 1, 2014; 37:2763-2773
Emerging Technologies and Therapeutics




li

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum

Itamar Raz
Jun 1, 2013; 36:1779-1788
Diabetes Care Expert Forum




li

Consensus Development Conference on Insulin Resistance: 5-6 November 1997

American Diabetes Association
Feb 1, 1998; 21:310-314
Consensus Development Conference Report




li

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Robert R. Henry
Dec 1, 2015; 38:2258-2265
Special Article Collection: Insulin




li

Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

John M. Lachin
Jan 1, 2014; 37:39-43
DCCT/EDIC 30th Anniversary Summary Findings




li

Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study

Joseph Henson
Jan 1, 2016; 39:130-138
IDF-ADA Translational Symposium




li

A Low-Glycemic Load Diet Facilitates Greater Weight Loss in Overweight Adults With High Insulin Secretion but Not in Overweight Adults With Low Insulin Secretion in the CALERIE Trial

Anastassios G. Pittas
Dec 1, 2005; 28:2939-2941
BR Clinical Care/Education/Nutrition




li

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Matthew C. Riddle
Oct 1, 2014; 37:2755-2762
Emerging Technologies and Therapeutics




li

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial

TODAY Study Group
Jun 1, 2013; 36:1735-1741
TODAY Study




li

A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves

Mary M Tai
Feb 1, 1994; 17:152-154
Short Report




li

Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state

Gary F Lewis
Apr 1, 1996; 19:390-393
Symposium On Insulin Resistance




li

Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Catherine L. Martin
Jan 1, 2014; 37:31-38
DCCT/EDIC 30th Anniversary Summary Findings




li

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll
Jun 1, 2007; 30:1608-1610
BR Emerging Treatments and Technologies




li

Insulinotropic Action of Glucagonlike Peptide-I-(7-37) in Diabetic and Nondiabetic Subjects

David M Nathan
Feb 1, 1992; 15:270-276
Short Report




li

Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association

Caroline S. Fox
Sep 1, 2015; 38:1777-1803
Scientific Statement




li

Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women

Dario Giugliano
Oct 1, 1993; 16:1387-1390
Short Report




li

Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial

Saila B. Koivusalo
Jan 1, 2016; 39:24-30
Considerations in the Management of Gestational Diabetes Mellitus




li

Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endo

Gina Agiostratidou
Dec 1, 2017; 40:1622-1630
Continuous Glucose Monitoring and Risk of Hypoglycemia




li

Stress and Diabetes Mellitus

Richard S Surwit
Oct 1, 1992; 15:1413-1422
Behavioral Diabetes Series




li

Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and {beta}-Cell Function in TODAY

TODAY Study Group
Jun 1, 2013; 36:1749-1757
TODAY Study




li

Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association

Sarah D. de Ferranti
Oct 1, 2014; 37:2843-2863
Scientific Statement




li

Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis

Henry N Ginsberg
Sep 1, 1991; 14:839-855
Diet and Diabetes




li

Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis

Alison J. Dunkley
Apr 1, 2014; 37:922-933
Current Concepts of Type 2 Diabetes Prevention




li

Psychological Insulin Resistance in Patients With Type 2 Diabetes: The scope of the problem

William H. Polonsky
Oct 1, 2005; 28:2543-2545
BR Epidemiology/Health Services/Psychosocial Research




li

Concentrations of Serum Vitamin D and the Metabolic Syndrome Among U.S. Adults

Earl S. Ford
May 1, 2005; 28:1228-1230
BR Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes




li

Improvement in Outcomes of Clinical Islet Transplantation: 1999-2010

Franca B. Barton
Jul 1, 2012; 35:1436-1445
Diabetes Care Symposium